ASCO Survey on COVID-19 in Oncology (ASCO) Registry
Closing the COVID-19 and Cancer Data Gap

Friday, June 12, 2020
Participants

Richard L. Schilsky, MD, FACP, FSCT, FASCO
Chief Medical Officer, Executive Vice President, American Society of Clinical Oncology

Randall A. Oyer, MD
Medical Director, Oncology Program, Penn Medicine Lancaster General Health; 2020-21 President, Association of Community Cancer Centers
Background

- National medical emergency → Opportunity for ASCO to assist the oncology community by gathering information

- Critical need to capture and analyze data on clinical care
  - Analyze distribution of symptoms and severity of COVID-19 among people with cancer
  - Examine impact of COVID-19 on cancer treatment and outcomes
  - Document adaptations of cancer care to the pandemic
## Types of Data Collected

<table>
<thead>
<tr>
<th>Patient Data</th>
<th>Practice Data</th>
</tr>
</thead>
</table>
| • Confirmed COVID-19 Diagnosis and  
  o Initiating treatment for new diagnosis  
  o Clinically evident cancer receiving anti-cancer treatment  
  o Clinically evident cancer receiving supportive care only  
  o Disease-free but receiving adjuvant therapy within 1 year after surgical resection | • Number of confirmed COVID-19 cases  
 • Use of telemedicine  
 • Modifications of infusions, other treatments  
 • Screening/triaging processes  
 • Physical changes to offices  
 • Drug and PPE shortages  
 • Staffing changes |
Data Collection

- Practice executes research participation & data use agreement with ASCO

- Two data entry options:
  - Submit data to ASCO via web-based REDCap forms
    - ASCO will de-identify data and return data to practice for their own use
  - Collect data locally using “cloned” REDCap project
    - Practices upload data to ASCO at monthly intervals

- ASCO Registry qualifies as High-weighted Practice Improvement Activity under the Merit-based Incentive Payment System (MIPS)

- Agreement and data capture forms can be found online:
  - [asco.org/asco-coronavirus-information/coronavirus-registry](asco.org/asco-coronavirus-information/coronavirus-registry)
Deliverables

- Periodic reports on estimates of disease severity, treatment modifications, and clinical outcomes of patients
  - Data summaries to participating practices
  - Publicly available reports to inform patients and clinicians

- Scientific manuscripts for peer-reviewed publication

- Registry data in ASCO Data Library will be available to qualified researchers
Current Status

- More than 100 practices currently in approval process
- 33 practices in 21 states fully enrolled
- Data on >100 patients already entered
- 80% of practices enrolled are ACCC members – THANK YOU!
Initial Results Regarding Practice Changes

- 20 sites from 17 practices across 15 states
  - 3 academic, 9 hospital/health-system owned, and 5 physician-owned
- 90% reported new use of telemedicine
  - 85% conducted some or all routine visits for patients not in active therapy by telemedicine; 15% delayed some routine visits
- Lab collection: 60% allow collection closer to home
- 40% experienced staffing reductions/changes
  - Due to reassignment, COVID-19, and reduced scheduling of patient visits
THANK YOU

To enroll in the ASCO Registry, visit:
asco.org/asco-coronavirus-information/coronavirus-registry

Questions? Email: CENTRA@asco.org
We Always Want to Do Better for Our Patients

- We are informed by scientific literature
- We are guided by trusted partners, especially ASCO and ACCC
- We know that the most robust information comes from having a strong data set
COVID-19 Hits in a Data-Free Zone: One Community’s Approach

- Organized twice weekly COVID-19 Community Oncology Cooperative (COC)
- Four medical oncology practices invited
- Half-hour conference call at 7:00 AM
- Prepared topics and open discussion
- Review of early literature, news reports, and institutional experience
Lancaster COVID-19 COC

- Which cancer patients are at greatest risk?
- What are the complications and outcomes?
- What are the best treatment(s) and management situations?
- What should we do about patients’ anti-cancer treatment(s)?
- What should we do in our practices to limit spread?
ASCO Registry

- The data set is in the community
- We need the answers
- It is our opportunity and responsibility to participate
Lancaster General Penn Medicine Experience

- Opening the trial was easy
- IRB exemption
- Research exemption
- Entered first two patients, 15 minutes each
- Follow up is easy
- Staff feel good about participating
Patients Desirous of Participating in Research

- Shared ACCC and ASCO goals
- Bridge the gap between the university and the community
- Be sure that all Americans share equally in advances from cancer research
The Time to Act is NOW

- Please join the ASCO Registry
- We need your collaboration on these urgent scientific questions
- Help us reach as many people as possible
ACCC COVID-19 Resources
accc-cancer.org/COVID-19

• Weekly Webcast Series
  • Weathering the COVID-19 Storm: One Program’s Care Coordination Experience (Friday, June 19)
  • Green Light for Cancer Research During COVID-19 (Friday, June 26)

• CANCER BUZZ Mini-Podcasts
  • COVID-19 vs. Biocontainment; Telemedicine; Drive-Thru COVID-19 Screenings; COVID-19 & Oral Oncolytics; Urban & Rural Cancer Care

• Evidence-Based Guidelines
• Peer-to-Peer Discussions on ACCCeXchange